A leucine to serine substitution at position 389 (L389S) was introduced in exon 10 and a loxP-flanked neomycin resistance was inserted upstream of exon 10 and then removed via cre-mediated recombination. The L389S mutation is one of two identified to date in individuals with amyotrophic lateral sclerosis type 4 (ALS4).